US 12005061
Ophthalmic formulations of methotrexate
granted A61KA61K31/519A61K47/02
Quick answer
US patent 12005061 (Ophthalmic formulations of methotrexate) held by Aldeyra Therapeutics, Inc. expires Mon Jun 06 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Aldeyra Therapeutics, Inc.
- Grant date
- Tue Jun 11 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jun 06 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 27
- CPC classes
- A61K, A61K31/519, A61K47/02, A61K47/10, A61K47/26